CHICAGO (Reuters) - A long-term study of brain scans in multiple sclerosis patients showed only about half of the patients who took the drug interferon beta 1-b got a long-lasting benefit, U.S. researchers said on Monday.
CHICAGO (Reuters) - A long-term study of brain scans in multiple sclerosis patients showed only about half of the patients who took the drug interferon beta 1-b got a long-lasting benefit, U.S. researchers said on Monday.
